Are small caps finally having their moment? With the big end of town looking stretched, is it time to take profits out of the banks and blue chips? And which companies could be the next JB Hi-Fi?
Peter Switzer and guests break down reporting season, the shift from big caps to small and mid caps, and the stocks catching investor attention right now. Plus, a deep dive into payments, retailers, and the rise of AI in business.
Are small caps finally having their moment? With the big end of town looking stretched, is it time to take profits out of the banks and blue chips? And which companies could be the next JB Hi-Fi?
Join Peter Switzer and Paul Rickard for their take on the big money stories and how they affect you in our final Mad about Money of the year.
On this week's show, Burman Invest's Julia Lee, Tribeca Investment Partners' Jun Bei Liu and Switzer's Paul Rickard join Peter Switzer.
Dr Ross Walker discusses the longest-running trial in relation to multivitamins and the potential benefits of long-term multivitamin use.
Join Peter Switzer and Paul Rickard for their take on the latest money news and how it affects you.
In this week's show, Peter Switzer speaks to Adam Dawes, Bevan Slattery, Julia Lee, Paul Rickard, Ying Yi Ann Cheng and Michael Gable.
Dr Ross Walker points out some issues with recent studies that have suggested multivitamins do nothing.
Join Peter Switzer and Paul Rickard for the latest episode of Mad about Money.
On this week's investing show, Peter Switzer is joined by Julia Lee from Burman Invest, Rudi Filapek-VanDyck from FNArena, Jun Bei Liu from Tribeca Investment Partners and Paul Rickard.
Dr Ross Walker talks about new evidence of the coronavirus, its fatality rates and possible mutations.
Join Peter Switzer and Paul Rickard for the latest episode of Mad about Money.
On this week's show, Peter Switzer speaks to Shaw and Partners' Adam Dawes, Burman Invest's Julia Lee, AMP Capital's Shane Oliver, Switzer's Paul Rickard and nabtrade's Gemma Dale.
Dr Ross Walker looks at the differences between the Oxford and Pfizer vaccine trials and shares the promising results from both.
Fill in the form below to subscribe to Switzer Daily and get our latest articles, videos and podcasts sent straight to your inbox
